Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Retina. 2013 May;33(5):946–952. doi: 10.1097/IAE.0b013e3182753b12

Fig. 1.

Fig. 1

Image montages illustrating clearance patterns of I-124 bevacizumab (top) and I-124 ranibizumab (bottom) within the vitreous cavity after pars plana vitrectomy in a rabbit model. Note the I-124 accumulation in the thyroid gland. Range of acquisition of radioactive emission is 10% to 75%.